Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

Ningbo No. 1 Hospital

Status: Enrolling

Conditions: Biological Age; Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes Mellitus (T2DM)

Treatments: Other: Observational

Study type: Observational

Funder types: Other

Identifiers

NCT06984510

2025-070RS-01

MR-33-25-026098 (Registry Identifier)

Details and patient eligibility

About

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Enrollment: 2,720 estimated patients

Sex: All

Ages: 20 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Abdominal ultrasound data available in annual health check-up records
2. At least one of the following five metabolic indicators recorded annually:

(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c)

Exclusion criteria

1. Age <20 or >90 years
2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)
3. Type 2 diabetes mellitus at baseline
4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)

Trial design

2,720 participants in 2 patient groups

MASLD group

Description:

participants with MASLD at baseline

Treatment:

Other: Observational

non-MASLD group

Description:

participants without MASLD at baseline

Treatment:

Other: Observational